Compare RGTI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | ERAS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | 164 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.5B |
| IPO Year | N/A | 2021 |
| Metric | RGTI | ERAS |
|---|---|---|
| Price | $20.53 | $11.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $30.78 | $14.25 |
| AVG Volume (30 Days) | ★ 51.1M | 4.5M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $225.06 | N/A |
| Revenue Next Year | $99.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $1.24 |
| 52 Week High | $58.15 | $24.28 |
| Indicator | RGTI | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 47.02 |
| Support Level | $14.51 | $9.80 |
| Resistance Level | $27.16 | $16.14 |
| Average True Range (ATR) | 2.64 | 0.98 |
| MACD | -0.15 | 0.36 |
| Stochastic Oscillator | 37.66 | 41.68 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.